The economic burden of metastatic breast cancer in Spain
ObjectivesThe study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.MethodsAn incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2020-01, Vol.27 (1), p.19-24 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 24 |
|---|---|
| container_issue | 1 |
| container_start_page | 19 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 27 |
| creator | Bermejo de las Heras, Begoña Cortes Ramon y Cajal, Javier Galve Calvo, Elena de la Haba Rodriguez, Juan Garcia Mata, Jesus Moreno Anton, Fernando Pelaez Fernandez, Ignacio Rodriguez-Lescure, Alvaro Rodriguez Sanchez, Cesar A Ruiz-Borrego, Manuel Remak, Edit Barra, Magdolna Rivero, Maria Soto Alvarez, Javier |
| description | ObjectivesThe study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.MethodsAn incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles.ResultsThe incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2−/HR+, 520 HER2+/HR+, 324 HER2+/HR−, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2−/HR+, 2.82 years for HER2+/HR− and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR−and €94,572 for triple negative patients over 5 years.ConclusionsThe economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2−/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs. |
| doi_str_mv | 10.1136/ejhpharm-2017-001453 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6992969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2356616150</sourcerecordid><originalsourceid>FETCH-LOGICAL-b517t-586fb60fde39fb9346f7a40b7e7f61031cb59c2e69f3187a109246290ae96c753</originalsourceid><addsrcrecordid>eNqNkU9LHEEQxRtRVHS_gYSBXHIZrf4705dAEBMFIQf13HT3Vruz7HRvumcCfntnWXcTcwieqqj6vUcVj5ALCpeUcnWFy8V6YXNfM6BNDUCF5AfklIFoaq2VONz3Up2QWSmdA8l5qwXXx-SEM1ACWnFK2scFVuhTTH3nKzfmOcYqharHwZbBDpthxqmtvI0ec9XF6mFtu3hOjoJdFZy91TPy9P3m8fq2vv_54-76233tJG2GWrYqOAVhjlwHp7lQobECXINNUBQ49U5qz1DpwGnbWAqaCcU0WNTKN5Kfka9b3_Xoepx7jEO2K7POXW_zi0m2M-83sVuY5_TbKK2ZVnoy-PJmkNOvEctg-q54XK1sxDQWw7hUiioqYUI__4Mu05jj9N5EiZZJALYxFFvK51RKxrA_hoLZpGN26ZhNOmabziT79Pcje9Euiwm42gKuX37UEv4o9qf-V_IKB0qqdQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2348250029</pqid></control><display><type>article</type><title>The economic burden of metastatic breast cancer in Spain</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bermejo de las Heras, Begoña ; Cortes Ramon y Cajal, Javier ; Galve Calvo, Elena ; de la Haba Rodriguez, Juan ; Garcia Mata, Jesus ; Moreno Anton, Fernando ; Pelaez Fernandez, Ignacio ; Rodriguez-Lescure, Alvaro ; Rodriguez Sanchez, Cesar A ; Ruiz-Borrego, Manuel ; Remak, Edit ; Barra, Magdolna ; Rivero, Maria ; Soto Alvarez, Javier</creator><creatorcontrib>Bermejo de las Heras, Begoña ; Cortes Ramon y Cajal, Javier ; Galve Calvo, Elena ; de la Haba Rodriguez, Juan ; Garcia Mata, Jesus ; Moreno Anton, Fernando ; Pelaez Fernandez, Ignacio ; Rodriguez-Lescure, Alvaro ; Rodriguez Sanchez, Cesar A ; Ruiz-Borrego, Manuel ; Remak, Edit ; Barra, Magdolna ; Rivero, Maria ; Soto Alvarez, Javier</creatorcontrib><description>ObjectivesThe study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.MethodsAn incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles.ResultsThe incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2−/HR+, 520 HER2+/HR+, 324 HER2+/HR−, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2−/HR+, 2.82 years for HER2+/HR− and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR−and €94,572 for triple negative patients over 5 years.ConclusionsThe economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2−/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2017-001453</identifier><identifier>PMID: 32064084</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Biomarkers ; Breast cancer ; Cancer therapies ; Cost estimates ; costs of illness ; direct costs ; Disease prevention ; Drug dosages ; Epidermal growth factor ; Expenditures ; Illnesses ; Industrialized nations ; Medical prognosis ; Metastasis ; metastatic breast cancer ; Mortality ; Original Research ; Patients ; Population ; resource utilisation ; treatment patterns</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2020-01, Vol.27 (1), p.19-24</ispartof><rights>European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2020 European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b517t-586fb60fde39fb9346f7a40b7e7f61031cb59c2e69f3187a109246290ae96c753</citedby><cites>FETCH-LOGICAL-b517t-586fb60fde39fb9346f7a40b7e7f61031cb59c2e69f3187a109246290ae96c753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992969/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992969/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32064084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bermejo de las Heras, Begoña</creatorcontrib><creatorcontrib>Cortes Ramon y Cajal, Javier</creatorcontrib><creatorcontrib>Galve Calvo, Elena</creatorcontrib><creatorcontrib>de la Haba Rodriguez, Juan</creatorcontrib><creatorcontrib>Garcia Mata, Jesus</creatorcontrib><creatorcontrib>Moreno Anton, Fernando</creatorcontrib><creatorcontrib>Pelaez Fernandez, Ignacio</creatorcontrib><creatorcontrib>Rodriguez-Lescure, Alvaro</creatorcontrib><creatorcontrib>Rodriguez Sanchez, Cesar A</creatorcontrib><creatorcontrib>Ruiz-Borrego, Manuel</creatorcontrib><creatorcontrib>Remak, Edit</creatorcontrib><creatorcontrib>Barra, Magdolna</creatorcontrib><creatorcontrib>Rivero, Maria</creatorcontrib><creatorcontrib>Soto Alvarez, Javier</creatorcontrib><title>The economic burden of metastatic breast cancer in Spain</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><addtitle>Eur J Hosp Pharm</addtitle><description>ObjectivesThe study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.MethodsAn incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles.ResultsThe incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2−/HR+, 520 HER2+/HR+, 324 HER2+/HR−, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2−/HR+, 2.82 years for HER2+/HR− and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR−and €94,572 for triple negative patients over 5 years.ConclusionsThe economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2−/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.</description><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cost estimates</subject><subject>costs of illness</subject><subject>direct costs</subject><subject>Disease prevention</subject><subject>Drug dosages</subject><subject>Epidermal growth factor</subject><subject>Expenditures</subject><subject>Illnesses</subject><subject>Industrialized nations</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>metastatic breast cancer</subject><subject>Mortality</subject><subject>Original Research</subject><subject>Patients</subject><subject>Population</subject><subject>resource utilisation</subject><subject>treatment patterns</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkU9LHEEQxRtRVHS_gYSBXHIZrf4705dAEBMFIQf13HT3Vruz7HRvumcCfntnWXcTcwieqqj6vUcVj5ALCpeUcnWFy8V6YXNfM6BNDUCF5AfklIFoaq2VONz3Up2QWSmdA8l5qwXXx-SEM1ACWnFK2scFVuhTTH3nKzfmOcYqharHwZbBDpthxqmtvI0ec9XF6mFtu3hOjoJdFZy91TPy9P3m8fq2vv_54-76233tJG2GWrYqOAVhjlwHp7lQobECXINNUBQ49U5qz1DpwGnbWAqaCcU0WNTKN5Kfka9b3_Xoepx7jEO2K7POXW_zi0m2M-83sVuY5_TbKK2ZVnoy-PJmkNOvEctg-q54XK1sxDQWw7hUiioqYUI__4Mu05jj9N5EiZZJALYxFFvK51RKxrA_hoLZpGN26ZhNOmabziT79Pcje9Euiwm42gKuX37UEv4o9qf-V_IKB0qqdQ</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Bermejo de las Heras, Begoña</creator><creator>Cortes Ramon y Cajal, Javier</creator><creator>Galve Calvo, Elena</creator><creator>de la Haba Rodriguez, Juan</creator><creator>Garcia Mata, Jesus</creator><creator>Moreno Anton, Fernando</creator><creator>Pelaez Fernandez, Ignacio</creator><creator>Rodriguez-Lescure, Alvaro</creator><creator>Rodriguez Sanchez, Cesar A</creator><creator>Ruiz-Borrego, Manuel</creator><creator>Remak, Edit</creator><creator>Barra, Magdolna</creator><creator>Rivero, Maria</creator><creator>Soto Alvarez, Javier</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>The economic burden of metastatic breast cancer in Spain</title><author>Bermejo de las Heras, Begoña ; Cortes Ramon y Cajal, Javier ; Galve Calvo, Elena ; de la Haba Rodriguez, Juan ; Garcia Mata, Jesus ; Moreno Anton, Fernando ; Pelaez Fernandez, Ignacio ; Rodriguez-Lescure, Alvaro ; Rodriguez Sanchez, Cesar A ; Ruiz-Borrego, Manuel ; Remak, Edit ; Barra, Magdolna ; Rivero, Maria ; Soto Alvarez, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b517t-586fb60fde39fb9346f7a40b7e7f61031cb59c2e69f3187a109246290ae96c753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cost estimates</topic><topic>costs of illness</topic><topic>direct costs</topic><topic>Disease prevention</topic><topic>Drug dosages</topic><topic>Epidermal growth factor</topic><topic>Expenditures</topic><topic>Illnesses</topic><topic>Industrialized nations</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>metastatic breast cancer</topic><topic>Mortality</topic><topic>Original Research</topic><topic>Patients</topic><topic>Population</topic><topic>resource utilisation</topic><topic>treatment patterns</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bermejo de las Heras, Begoña</creatorcontrib><creatorcontrib>Cortes Ramon y Cajal, Javier</creatorcontrib><creatorcontrib>Galve Calvo, Elena</creatorcontrib><creatorcontrib>de la Haba Rodriguez, Juan</creatorcontrib><creatorcontrib>Garcia Mata, Jesus</creatorcontrib><creatorcontrib>Moreno Anton, Fernando</creatorcontrib><creatorcontrib>Pelaez Fernandez, Ignacio</creatorcontrib><creatorcontrib>Rodriguez-Lescure, Alvaro</creatorcontrib><creatorcontrib>Rodriguez Sanchez, Cesar A</creatorcontrib><creatorcontrib>Ruiz-Borrego, Manuel</creatorcontrib><creatorcontrib>Remak, Edit</creatorcontrib><creatorcontrib>Barra, Magdolna</creatorcontrib><creatorcontrib>Rivero, Maria</creatorcontrib><creatorcontrib>Soto Alvarez, Javier</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bermejo de las Heras, Begoña</au><au>Cortes Ramon y Cajal, Javier</au><au>Galve Calvo, Elena</au><au>de la Haba Rodriguez, Juan</au><au>Garcia Mata, Jesus</au><au>Moreno Anton, Fernando</au><au>Pelaez Fernandez, Ignacio</au><au>Rodriguez-Lescure, Alvaro</au><au>Rodriguez Sanchez, Cesar A</au><au>Ruiz-Borrego, Manuel</au><au>Remak, Edit</au><au>Barra, Magdolna</au><au>Rivero, Maria</au><au>Soto Alvarez, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The economic burden of metastatic breast cancer in Spain</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><addtitle>Eur J Hosp Pharm</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>27</volume><issue>1</issue><spage>19</spage><epage>24</epage><pages>19-24</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>ObjectivesThe study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.MethodsAn incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles.ResultsThe incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2−/HR+, 520 HER2+/HR+, 324 HER2+/HR−, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2−/HR+, 2.82 years for HER2+/HR− and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR−and €94,572 for triple negative patients over 5 years.ConclusionsThe economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2−/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>32064084</pmid><doi>10.1136/ejhpharm-2017-001453</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2020-01, Vol.27 (1), p.19-24 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6992969 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biomarkers Breast cancer Cancer therapies Cost estimates costs of illness direct costs Disease prevention Drug dosages Epidermal growth factor Expenditures Illnesses Industrialized nations Medical prognosis Metastasis metastatic breast cancer Mortality Original Research Patients Population resource utilisation treatment patterns |
| title | The economic burden of metastatic breast cancer in Spain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A36%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20economic%20burden%20of%20metastatic%20breast%20cancer%20in%20Spain&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Bermejo%20de%20las%20Heras,%20Bego%C3%B1a&rft.date=2020-01-01&rft.volume=27&rft.issue=1&rft.spage=19&rft.epage=24&rft.pages=19-24&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2017-001453&rft_dat=%3Cproquest_pubme%3E2356616150%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2348250029&rft_id=info:pmid/32064084&rfr_iscdi=true |